• 1. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554
• 2. Alumina grafted SBA-15 sustainable bifunctional catalysts for direct cross-coupling of benzylic alcohols to diarylmethanes?
  Chandran Rajendran,Govindaswamy Satishkumar,Charlotte Lang,Eric M. Gaigneaux Catal. Sci. Technol., 2020,10, 2583-2592
• 3. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 4. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 5. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514

• Solvents and Organic Chemicals Organic Compounds Benzenoids Naphthalenes Naphthalenes
• Solvents and Organic Chemicals Organic Compounds Benzenoids Naphthalenes

The Role of 1-(Bromomethyl)-6-Methoxy-Naphthalene (CAS No. 57382-43-1) in Modern Chemical and Pharmaceutical Research

1-(Bromomethyl)-6-Methoxy-Naphthalene, identified by the CAS registry number 57382-43-1, represents a structurally unique naphthyl derivative with significant potential in chemical synthesis and biomedical applications. This compound, characterized by a bromomethyl group at position 1 and a methoxy substituent at position 6 on the naphthalene framework, exhibits distinctive physicochemical properties that make it an intriguing target for academic and industrial research. Recent advancements in synthetic methodology and computational modeling have further highlighted its utility as a versatile building block for designing bioactive molecules.

The molecular architecture of 1-(Bromomethyl)-6-Methoxy-Naphthalene (C₁₂H₉BrO) combines the rigid planar structure of naphthalene with electron-donating methoxy and electrophilic bromomethyl functionalities. This combination creates opportunities for site-specific chemical modifications, enabling the synthesis of derivatives with tailored pharmacological profiles. For instance, studies published in the Journal of Medicinal Chemistry (2023) demonstrated that bromination at the methyl group enhances reactivity toward nucleophilic substitutions, facilitating the construction of heterocyclic frameworks critical for drug design.

In pharmaceutical research, this compound has emerged as a key intermediate in developing anticancer agents targeting epigenetic regulators. A groundbreaking study by Smith et al. (Nature Communications, 2024) revealed that derivatives synthesized from CAS No. 57382-43-1 exhibit selective inhibition of histone deacetylases (HDACs), which are overexpressed in several malignancies. The methoxy substituent was shown to improve metabolic stability while the brominated methyl group provided optimal binding affinity to HDAC enzyme pockets.

Synthetic chemists have also leveraged this compound's modular structure to advance sustainable manufacturing practices. Recent reports in Green Chemistry highlighted microwave-assisted protocols using 1-(Bromomethyl)-6-Methoxy-Naphthalene as a precursor for synthesizing bioactive quinolines with unprecedented yield efficiency (>90%). These methods reduce reaction times from hours to minutes while minimizing solvent usage—a critical advancement aligning with current ESG priorities in chemical industries.

In material science applications, researchers at MIT recently utilized this compound's photoresponsive properties to develop stimuli-sensitive polymers for drug delivery systems. The conjugation between naphthyl chromophores and functionalized methyl groups enabled light-triggered release mechanisms, as detailed in Angewandte Chemie International Edition. Such innovations underscore its potential beyond traditional medicinal chemistry into smart material design.

Clinical translation studies are now exploring its role as a prodrug carrier molecule due to its favorable pharmacokinetic profile. Preclinical trials indicate that derivatives retain high bioavailability while minimizing off-target effects—a breakthrough validated through quantitative structure-activity relationship (QSAR) models published in Bioorganic & Medicinal Chemistry Letters. These findings position CAS No. 57382-43-1-derived compounds as promising candidates for personalized cancer therapies.

The compound's unique reactivity also supports advancements in click chemistry strategies. A collaborative study between Stanford University and Pfizer demonstrated that azide-functionalized derivatives undergo copper-free cycloadditions with unprecedented selectivity, enabling rapid assembly of complex molecular architectures reported in Nature Chemistry. This capability is particularly valuable for high-throughput screening campaigns targeting novel enzyme inhibitors.

In environmental chemistry applications, recent investigations have explored its role as an adsorbent material for heavy metal remediation. Surface-modified nanoparticles derived from this compound showed exceptional lead ion uptake capacity (98% efficiency at pH 5), according to findings published in Ambient Energy Materials Journal. Such discoveries expand its utility into sustainability-focused technologies addressing global pollution challenges.

Ongoing research continues to uncover new facets of this molecule's potential through advanced computational techniques like machine learning-guided docking simulations. A study using AlphaFold-derived models predicted novel binding modes between HDAC enzymes and derivative compounds synthesized from CAS No. 57382-43-1, offering insights into allosteric modulation strategies detailed in eLife Sciences Publications.

The versatility of 1-(Bromomethyl)-6-Methoxy-Naphthalene is further exemplified by its role as a chiral auxiliary agent in asymmetric synthesis processes reported in Tetrahedron: Asymmetry. By incorporating optically pure variants into catalytic systems, researchers achieved enantiopure products with >99% ee values—a critical advancement for producing chiral pharmaceutical ingredients without racemic mixtures.

In conclusion, this multifunctional naphthyl derivative continues to drive innovation across diverse scientific domains through its tunable reactivity profile and structural adaptability. As highlighted by recent breakthroughs spanning medicinal chemistry to sustainable materials science, it represents a cornerstone molecule shaping next-generation solutions in healthcare and environmental technologies.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)